MedTrace Logo

Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction

NCT04331132 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2022-08-11

No results posted yet for this study

Summary

Renal dysfunction, which comprises 10%-40% of acute heart failure patients (AHF), plays an important role in diuretic resistance mechanism. DR-AHF was designed to demonstrate the effectiveness of early tolvaptan (a vasopressin-2 receptor antagonist) add-on therapy in acute heart failure patients with renal dysfunction and clinical evidence of loop diuretic resistance.

Conditions

  • Acute Heart Failure

Interventions

DRUG

Tolvaptan 15 MG

vasopressin-2 receptor antagonist 15mg once daily is added-on to the conventional diuretic strategy

Sponsors & Collaborators

  • Otsuka Pharmaceutical Vietnam

    collaborator INDUSTRY

  • Gia Dinh People Hospital

    lead OTHER

Principal Investigators

  • Hai H. Nguyen, Ph.D · Cardiology Department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2023-06-30
Completion
2023-07-26

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04331132 on ClinicalTrials.gov